FDA approves Moderna's mRNA flu vaccine, the first to use the technology
The Food and Drug Administration has approved Moderna's mFlusiva, the first influenza vaccine built on messenger RNA (mRNA) technology, extending a platform that was administered billions of times worldwide during the Covid-19 pandemic into the realm of seasonal flu prevention.
Conventional flu vaccines are typically produced over several months using egg-based manufacturing and rely on the World Health Organization's forecast of which viral strains will circulate that season. mRNA technology can compress that production timeline to weeks, allowing formulations to be updated more quickly if predictions shift.
In clinical trials, mFlusiva showed an immune response at least equivalent to traditional vaccines, and stronger results in some age groups. Moderna presented data to the FDA indicating the vaccine produced a notably robust immune response in older adults, a population that often responds less well to standard flu shots.
Experts say the approval's significance extends beyond efficacy numbers. The flexibility of the mRNA platform strengthens the case for future combination vaccines targeting both flu and Covid-19; Moderna has already disclosed it is developing such a combined shot.
On safety, regulators noted that monitoring should continue for myocarditis, a rare side effect observed with mRNA Covid-19 vaccines. The FDA said post-approval surveillance studies would help clarify the scale of that risk in the flu vaccine context.
Health economists expect that manufacturing costs for mRNA-based flu vaccines may initially exceed those of conventional shots, though the gap could narrow as production scales up. Insurance coverage and pricing decisions will heavily influence how quickly the vaccine reaches wide use.
Vaccine specialists say the biggest advantage of mRNA technology is its capacity for rapid response. When a new flu strain emerges, updating the formulation can happen far faster than with traditional manufacturing methods.
The approval has also reignited discussion among health officials about pandemic preparedness. Some experts argue that expanding mRNA technology into seasonal flu means manufacturing infrastructure will be better positioned if another pandemic emerges.
Moderna plans to release mFlusiva in limited quantities this coming autumn season, with production scaling gradually over subsequent years. Company officials acknowledge it will likely take years before the vaccine fully displaces conventional formulations.
Experts expect patients and doctors will be able to choose between conventional and mRNA-based flu vaccines during this transition period, though many anticipate the mRNA platform could eventually become the standard for seasonal flu protection.
Read next
Can chewing gum lower HPV levels? What a new study found
Researchers found that a chewing gum formulated with specific compounds reduced oral HPV viral load by up to 93% in some study participants. The early-stage findings raise hope for a low-cost tool against a virus linked to a rising share of head and neck cancers.
Why sitting up straight may improve mood and decision-making
New research suggests posture does more than protect the back — sitting upright appears to influence mood, stress response and even decision-making speed. Scientists behind the study explain what the body-mind link reveals about everyday posture habits.
3 midlife health factors that could delay dementia by 13 years
A new long-term study has found that three modifiable health factors in midlife can delay the average onset of dementia by roughly 13 years. Researchers stress that addressing these factors in a person's 40s and 50s, rather than later in life, produces a substantially larger protective effect.
Could gut microbiome transplants be the next treatment for food allergies
Researchers are testing whether transplanting gut bacteria from healthy donors can retrain the immune systems of children with severe food allergies, starting with peanut allergy. Early-stage trials show promise, but scientists caution that questions about safety, mechanism and durability remain unresolved.
Jet lag: how sunlight and meal timing help travelers beat it faster
Jet lag disrupts the body's internal clock when travelers cross several time zones quickly. Sleep scientists say adjusting light exposure, meal timing and sleep schedules before and during a trip can meaningfully shorten recovery. Here is what the research actually recommends.